CN108210458B - 一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物 - Google Patents
一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物 Download PDFInfo
- Publication number
- CN108210458B CN108210458B CN201810314791.3A CN201810314791A CN108210458B CN 108210458 B CN108210458 B CN 108210458B CN 201810314791 A CN201810314791 A CN 201810314791A CN 108210458 B CN108210458 B CN 108210458B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- difluprednate
- composition according
- emulsion
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 title claims abstract description 31
- 229960004875 difluprednate Drugs 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000003242 anti bacterial agent Substances 0.000 title claims description 14
- 229940088710 antibiotic agent Drugs 0.000 title claims description 14
- 229940124307 fluoroquinolone Drugs 0.000 title claims description 14
- 239000000839 emulsion Substances 0.000 claims abstract description 30
- 239000003306 quinoline derived antiinfective agent Substances 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 10
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 claims description 9
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 claims description 9
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- 239000004359 castor oil Substances 0.000 claims description 7
- 235000019438 castor oil Nutrition 0.000 claims description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 7
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004327 boric acid Substances 0.000 claims description 6
- 239000000337 buffer salt Substances 0.000 claims description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 4
- 229960003405 ciprofloxacin Drugs 0.000 claims description 4
- 229940124274 edetate disodium Drugs 0.000 claims description 4
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002549 enoxacin Drugs 0.000 claims description 4
- 229960003923 gatifloxacin Drugs 0.000 claims description 4
- 229960003702 moxifloxacin Drugs 0.000 claims description 4
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 206010015958 Eye pain Diseases 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000013022 formulation composition Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物，该药物组合物可提高二氟泼尼酯乳液的光稳定性，同时该药物组合物还能提高氟喹诺酮类抗生素的抑菌能力。
Description
技术领域
本发明属于药物制剂领域，具体涉及一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物。
背景技术
二氟泼尼酯属于肾上腺皮质激素类药物，是泼尼松龙的二氟衍生物，具有较强的抗炎镇痛作用，副作用小。二氟泼尼酯乳液的临床试验显示该药可快速治疗眼科手术后的眼部炎症，安全有效，该药市场前景十分广阔。但是，由于二氟泼尼酯乳液光稳定性较差，需要避光处理，因此二氟泼尼酯乳液对包装的要求较高，这一定程度上限制了二氟泼尼酯乳液的储存与使用。
中国专利申请CN105120875B公开了一种含锌的二氟泼尼酯乳液组合物，该组合物在光照条件下的物理稳定性较好，但是该组合物没有解决二氟泼尼酯在光照后容易降解的问题。
发明内容
为了克服现有技术中的问题，本发明提供了一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物，所述的药物组合物包括以下组分：
二氟泼尼酯、氟喹诺酮类抗生素、吐温80、蓖麻油、甘油、依地酸二钠、缓冲盐、注射用水。
作为优选，所述氟喹诺酮类抗生素选自莫西沙星或其药用盐、加替沙星或其药用盐、依诺沙星或其药用盐、环丙沙星或其药用盐，更优选为莫西沙星或其药用盐，特别优选为盐酸莫西沙星。
作为优选，所述缓冲盐为硼酸与醋酸钠的组合。
作为进一步优选技术方案，所述药物组合物由以下组分组成：二氟泼尼酯0.5mg/mL，氟喹诺酮类抗生素0.5～21.8mg/mL，吐温80 20～100mg/mL，蓖麻油20～100mg/mL，甘油1～50mg/mL，依地酸二钠0.05～10mg/mL，缓冲盐0.1～20mg/mL，余量为注射用水。
作为更进一步优选的技术方案，所述氟喹诺酮类抗生素的浓度为3.27～21.8mg/mL。
作为优选，所述药物组合物的剂型为乳剂。
本发明的药物组合物的应用为预防或治疗眼部疼痛、炎症与感染。
本发明的药物组合物优选无菌并且具有适用于眼部使用的物理性能，比如渗透压与pH，渗透压优选为250～450mOsm，pH优选为4.5～6.5。
本发明的有益效果：
1)本发明的药物组合物可以显著提高二氟泼尼酯乳液的光稳定性，解决了二氟泼尼酯乳液遇光容易降解的问题，方便了二氟泼尼酯乳液的储存和使用。
2)本发明的药物组合物可以显著提高氟喹诺酮类抗生素(如盐酸莫西沙星)的杀菌能力，增强临床疗效。
具体实施方式
以下结合实施例具体说明本发明，本发明中的实施例仅仅用于说明本发明的技术方案，而非限定本发明的实质，并不因此将本发明限制在所述的实施例范围之中。凡是不背离本发明构思的变动或等同替代均在本发明的保护范围之内。实施例
实施例1～14的处方组成见表1与表2。
表1实施例1～7的处方组成
表2实施例8～14的处方组成
制备方法：将蓖麻油加热至约70℃，加入二氟泼尼酯溶解得到油相；另外将吐温80、甘油、依地酸二钠、醋酸钠和硼酸溶解于注射用水中，加热至约70℃，得到水相；将油相加入水相中，用高速均质机均质得到初乳；初乳中加入氟喹诺酮类抗生素(盐酸莫西沙星、加替沙星、依诺沙星或环丙沙星)，搅拌溶解，使用1N盐酸溶液与1N氢氧化钠溶液将乳液pH调节至目标pH，得到最终的乳剂。对比实施例
对比实施例1～9的处方组成见表3。
表3对比实施例1～9处方组成
对比实施例1的制备方法：将蓖麻油加热至约70℃，加入二氟泼尼酯溶解得到油相；另外将吐温80、甘油、依地酸二钠、醋酸钠和硼酸溶解于注射用水中，加热至约70℃，得到水相；将油相加入水相中，用高速均质机均质得到初乳，使用1N盐酸溶液与1N氢氧化钠溶液将初乳pH调节至目标pH，得到最终的乳剂。
对比实施例2～8的制备方法：将蓖麻油加热至约70℃，加入二氟泼尼酯溶解得到油相；另外将吐温80、甘油、依地酸二钠、醋酸钠和硼酸溶解于注射用水中，加热至约70℃，得到水相；将油相加入水相中，用高速均质机均质得到初乳，向初乳中加入妥布霉素，搅拌溶解，使用1N盐酸溶液与1N氢氧化钠溶液将乳液pH调节至目标pH，得到最终的乳剂。
对比实施例9的制备方法：将硼酸、氯化钠、盐酸莫西沙星溶于注射用水中，使用1N盐酸溶液与1N氢氧化钠溶液将溶液pH调节至目标pH，即得。
光照稳定性实验
根据ICH(人用药品注册技术国际协调会议)稳定性测试指南，实施光稳定性实验。将实施例1-14的乳剂与对比实施例1-8的乳剂灌装于LDPE滴眼瓶后，置于光照箱中，给予1.2×106Lux·Hr的光照总照度(近紫外能量不低于200w·Hr/m2)，光照24h后取样测定二氟泼尼酯含量(含量是指测定值与理论值的比值)，结果如下表：
表4实施例1-14的乳剂与对比实施例1-8的乳剂中的二氟泼尼酯的含量测定结果
实施例1-14的乳剂在光照后，二氟泼尼酯的降解程度均较小，当盐酸莫西沙星的浓度在3.27～21.8mg/mL范围时，二氟泼尼酯的含量变化均在5％以内，较为稳定；对比实施例1-8的乳剂在光照后，二氟泼尼酯的含量均小于1％，基本降解完全。
可见，含盐酸莫西沙星、加替沙星、依诺沙星与环丙沙星的药物组合物均可显著提高二氟泼尼酯乳液的光稳定性。
体外抑菌实验
取实施例6的乳剂与对比实施例9的溶液剂进行体外抑菌实验对比研究，实验过程遵循无菌操作的要求。
实验方法：取活化后的大肠杆菌、金黄色葡萄球菌，用0.85％的无菌氯化钠溶液制备成107～108浓度的菌液；分别各吸取25μL的菌液加入5mL样品溶液中，避光保存在20-25℃培养箱，6h与24h后，取样测定活菌数。
测定方法：量取上述经过培养箱培养后的样品溶液1ml，加入到含9ml 2％MgSO4水溶液的无菌试管中；充分混匀，用2％MgSO4水溶液稀释到1:104；吸取1ml稀释液于0.22μm滤膜，用800mL 2％MgSO4水溶液冲洗过滤，取出滤膜，菌面朝上贴于含2％MgSO4大豆酪蛋白琼脂培养基的平板上，于30～35℃培养1-3天，取出，计算菌落数并得出下降的lg值，测定结果见表5。
表5实施例6的乳剂与对比实施例9的溶液剂的体外抑菌实验结果
实施例6的乳剂与对比实施例9的溶液剂所含的盐酸莫西沙星浓度相同，但是实施例6的乳剂对大肠杆菌与金黄色葡萄球菌的杀灭效果明显强于对比实施例9的溶液剂，可见本发明的药物组合物提高了氟喹诺酮类抗生素(如盐酸莫西沙星)的杀菌能力。
Claims (8)
1.一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物，其特征在于所述的药物组合物由以下组分组成：二氟泼尼酯、氟喹诺酮类抗生素、吐温80、蓖麻油、甘油、依地酸二钠、缓冲盐、注射用水；其中，所述氟喹诺酮类抗生素选自其中一种或几种的组合：莫西沙星或其药用盐、加替沙星或其药用盐、依诺沙星或其药用盐、环丙沙星或其药用盐。
2.根据权利要求1所述的药物组合物，其特征在于所述氟喹诺酮类抗生素为莫西沙星或其药用盐。
3.根据权利要求1所述的药物组合物，其特征在于所述氟喹诺酮类抗生素为盐酸莫西沙星。
4.根据权利要求1所述的药物组合物，其特征在于所述缓冲盐为硼酸与醋酸钠的组合。
5.根据权利要求1-4中任意一项所述的药物组合物，其特征在于所述的药物组合物由以下组分组成：二氟泼尼酯0.5mg/mL，氟喹诺酮类抗生素0.5～21.8mg/mL，吐温80 20～100mg/mL，蓖麻油20～100mg/mL，甘油1～50mg/mL，依地酸二钠0.05～10mg/mL，缓冲盐0.1～20mg/mL，余量为注射用水。
6.根据权利要求5所述的药物组合物，其特征在于所述氟喹诺酮类抗生素的浓度为3.27～21.8mg/mL。
7.根据权利要求1所述的药物组合物，其特征在于所述药物组合物为乳剂。
8.如权利要求1所述的药物组合物的应用，其特征在于，所述的药物组合物用于制备预防或治疗眼部疼痛、炎症与感染的药物中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810314791.3A CN108210458B (zh) | 2018-04-10 | 2018-04-10 | 一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810314791.3A CN108210458B (zh) | 2018-04-10 | 2018-04-10 | 一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108210458A CN108210458A (zh) | 2018-06-29 |
| CN108210458B true CN108210458B (zh) | 2020-12-01 |
Family
ID=62657647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810314791.3A Active CN108210458B (zh) | 2018-04-10 | 2018-04-10 | 一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108210458B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564397A (zh) * | 2009-06-05 | 2009-10-28 | 山东省医药工业研究所 | 一种含有二氟泼尼酯和妥布霉素眼用或者耳鼻用组合物及其用途 |
| CN101564395A (zh) * | 2009-06-05 | 2009-10-28 | 山东省医药工业研究所 | 一种含有二氟泼尼酯和左氧氟沙星眼用或者耳鼻用组合物及其用途 |
-
2018
- 2018-04-10 CN CN201810314791.3A patent/CN108210458B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564397A (zh) * | 2009-06-05 | 2009-10-28 | 山东省医药工业研究所 | 一种含有二氟泼尼酯和妥布霉素眼用或者耳鼻用组合物及其用途 |
| CN101564395A (zh) * | 2009-06-05 | 2009-10-28 | 山东省医药工业研究所 | 一种含有二氟泼尼酯和左氧氟沙星眼用或者耳鼻用组合物及其用途 |
Non-Patent Citations (1)
| Title |
|---|
| DIFLUPREDNATE FOR INFLAMMATORY EYE DISORDERS;L. Mulki等;《Drugs of Today》;20111231;第47卷(第5期);第327-333页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108210458A (zh) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100353377B1 (ko) | 디클로페낙및토브라마이신을기재로하는약액 | |
| JP5441934B2 (ja) | レバミピドの医薬組成物 | |
| US9034918B2 (en) | Composition including at least one trans-cinnamaldehyde and the use thereof in the treatment of bacterial infections, specifically in the treatment of nosocomial infections | |
| JP2009114206A (ja) | 抗微生物活性を有する医薬組成物 | |
| WO2014143646A1 (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
| US11376283B2 (en) | Stem cell material, compositions, and methods of use | |
| WO2011013794A1 (ja) | 点眼用水性組成物 | |
| TW201733578A (zh) | 含多佐胺與溴莫尼定之醫藥組成物 | |
| TW201417814A (zh) | 包括瑞巴派特之醫藥組成物 | |
| WO2015125921A1 (ja) | 保存効力を有する医薬用水性組成物 | |
| CN108210458B (zh) | 一种含有氟喹诺酮类抗生素与二氟泼尼酯的药物组合物 | |
| RU2666961C2 (ru) | Эмульсионная композиция дифлюпредната, содержащая антимикробный металл | |
| CN109045044B (zh) | 一种复方药剂及其制备方法、用途 | |
| RU2745617C2 (ru) | Антисептическое средство, включающее меглюмин или его соль | |
| TWI828025B (zh) | 保存效果或光穩定性經改善之眼科藥用組成物 | |
| JP5461785B2 (ja) | 繰り返し感染予防用の医薬組成物 | |
| UA115454C2 (uk) | Композиція фінафлоксацину у вигляді суспензії | |
| RU2675813C2 (ru) | Эмульсионная композиция дифлупредната, содержащая цинк | |
| CN116570558B (zh) | 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用 | |
| Maslii et al. | Testing of antimicrobial activity of preservatives for dental gels development | |
| CN105999239A (zh) | 一种盐酸溶菌酶滴眼液及其制备方法和应用 | |
| CN115737551A (zh) | 一种氟苯尼考甲硝唑滴耳液及其制备方法 | |
| WO2024105689A1 (en) | Novel ophthalmic composition | |
| RU2581025C1 (ru) | Глазная лекарственная пленка с моксифлоксацином | |
| Singh et al. | Formulation and evaluation of in situ gellin g ocular system of ofloxacin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |